Department of Applied Health Science, School of Public Health, Indiana University, 1025 E. 7th Street, SPH 116, Bloomington, IN 47405, USA.
Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan, 400 North Ingalls, Ann Arbor, MI 48109, USA.
Addict Behav. 2018 Jan;76:348-354. doi: 10.1016/j.addbeh.2017.08.032. Epub 2017 Sep 5.
State-level prescription drug monitoring programs (PDMPs) have been implemented in most states. PDMPs enable registered prescribers to obtain real-time information on patients' prescription history to reduce non-medical use of controlled drugs. This study examined whether PDMP implementation and different levels of PDMP requirements were associated with physicians' patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
This is a secondary analysis study using cross-sectional national data. Patients with non-cancer chronic pain from the 2012 National Ambulatory Medical Care Survey were included (weighted N=81,018,131; unweighted N=3295). Heckman two-step selection procedure employing two logistic regressions was used to explore the associations between PDMP requirements and physicians' prescribing behaviors, controlling for physician characteristics, patient characteristics, physician-healthcare system interaction, and physician-patient relationship, guided by the Eisenberg's model of physician decision making.
State PDMP implementation status and requirement levels were not associated with physician opioid prescribing for non-cancer chronic pain treatment (p's ranged 0.30-0.32). Patients with Medicare coverage were more likely to be prescribed opioid analgesics than those with private health insurance (OR=1.55, p<0.01). Hispanic patients were less likely to be prescribed opioid analgesics than non-Hispanic white patients (OR=0.61, p<0.05).
Findings indicated that the effectiveness of PDMPs on physicians' opioid prescribing tendency for non-cancer chronic pain treatment could not be supported. Policy makers should be aware of the need for redesigning PDMPs regarding requirements and enforcement for prescribers and related stakeholders. Future studies also are needed to identify characteristics contributing to PDMP effectiveness in reducing non-medical use of prescription opioids.
大多数州都已实施了州级处方药物监测计划(PDMP)。PDMP 使注册的处方医师能够获取患者的处方史实时信息,以减少管制药物的非医疗用途。本研究考察了 PDMP 的实施情况以及不同级别的 PDMP 要求是否与医师为患有非癌症慢性疼痛的患者开具阿片类镇痛药的处方模式有关。
这是一项使用横截面全国数据的二次分析研究。研究纳入了 2012 年国家门诊医疗保健调查中的患有非癌症慢性疼痛的患者(加权 N=81,018,131;未加权 N=3295)。采用 Heckman 两步选择程序进行的两项逻辑回归分析,根据 Eisenberg 的医师决策模型,控制医师特征、患者特征、医师-医疗保健系统交互作用以及医师-患者关系,探讨 PDMP 要求与医师开具处方行为之间的关联。
州 PDMP 的实施情况和要求水平与非癌症慢性疼痛治疗中医师开具阿片类镇痛药的情况无关(p 值范围为 0.30-0.32)。有医疗保险的患者比有私人医疗保险的患者更有可能被开具阿片类镇痛药(OR=1.55,p<0.01)。西班牙裔患者比非西班牙裔白人患者更不可能被开具阿片类镇痛药(OR=0.61,p<0.05)。
研究结果表明,PDMP 对医师治疗非癌症慢性疼痛的阿片类药物开具倾向的有效性无法得到支持。政策制定者应意识到需要重新设计 PDMP,以针对医师和相关利益相关者制定要求并加以执行。未来还需要研究确定有助于 PDMP 减少处方类阿片药物非医疗使用的有效性的特征。